Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure

Circulation

Volumn 101, Issue 25, 2000, Pages 2922-2927

  Givertz, Michael M ^a   Colucci, Wilson S ^a   LeJemtel, Thierry H ^b   Gottlieb, Stephen S ^c   Hare, Joshua M ^d   Slawsky, Mara T ^e   Leier, Carl V ^f   Loh, Evan ^g   Nicklas, John M ^h   Lewis, Bruce E ⁱ  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Endothelin; Heart failure; Hemodynamics

Indexed keywords

ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; PLACEBO; SITAXSENTAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0034720820     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.25.2922     Document Type: Article

References (27)

1. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
2. Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J. 1997;18:254-258.
3. Tsutamoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427-1433.
4. Bialecki RA, Fisher CS, Murdoch WW, et al. Functional comparison of endothelin receptors in human and rat pulmonary artery smooth muscle. Am J Physiol. 1997;272:L211-L218.
5. de Nucci G, Thomas R, D'Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA. 1988;85:9797-9800.
6. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 1995;92:357-363.
7. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol. 1996;81:1510-1515.
8. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995; 346:732-736.
9. Sutsch G, Kiowski W, Yan X-W, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262-2268.
10. Cowburn PJ, Cleland JG, McArthur JD, et al. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)- receptor antagonist, in chronic heart failure. Lancet. 1998;352:201-202.
11. Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem. 1997;40:1690-1697.
12. Zellers TM, McCormick J, Wu Y. Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins. Am J Physiol. 1994;267:H139-H147.
13. Lippton HL, Hauth TA, Summer WR, et al. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. J Appl Physiol. 1989; 66:1008-1012.
14. Buchan KW, Magnusson H, Rabe KF, et al. Characterization of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46-2005. Eur J Pharmacol. 1994;260:221-226.
15. Higashi T, Ishizaki T, Shigemori K, et al. Pharmacological characterization of endothelin-induced rat pulmonary arterial dilatation. Br J Pharmacol. 1997;121:782-786.
16. McCulloch KM, Docherty CC, Morecroft I, et al. EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol. 1996;119:1125-1130.
17. Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation. 1994;90: 2780-2785.
18. Love MP, Haynes WG, Gray GA, et al. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996;94:2131-2137.
19. B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 1999;33:932-938.
20. Calderone A, Rouleau JL, de Champlain J, et al. Regulation of the endothelin-1 transmembrane signaling pathway: the potential role of agonist-induced desensitization in the coronary artery of the rapid ventricular pacing-overdrive dog model of heart failure. J Mol Cell Cardiol. 1993;25:895-903.
21. Ponicke K, Vogelsang M, Heinroth M, et al. Endothelin receptors in the failing and nonfailing human heart. Circulation. 1998;97:744-751.
22. Meyer M, Lehnart S, Pieske B, et al. Influence of endothelin 1 on human atrial myocardium-myocardial function and subcellular pathways. Basic Res Cardiol. 1996;91:86-93.
23. Fukuroda T, Kobayashi M, Ozaki S, et al. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol. 1994;76: 1976-1982.
24. Chen SJ, Chen YF, Opgenorth TJ, et al. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxiainduced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol. 1997;29:713-725.
25. Zamora MA, Dempsey EC, Walchak SJ, et al. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 1993;9: 429-433.
26. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982.
27. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 1997;80:15L-25L.